Biotech and pharma specialist Sanderling Ventures plans to raise a seventh fund, its first in seven years, coming on the heels of some recent exits, sources intimately familiar with the VC’s strategy told peHUB.com.
Sanderling, which did not use a placement agent for its 2004 $421 million fund, may take one on as it looks to reel in new LPs, one source said.
